Eli Lilly completes $2.4bn acquisition of DICE Therapeutics

Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More